What is JAGX's market cap?

$1.16M, based on the Nov 4 close of $0.50.

Does Jaguar Health pay a dividend?

No regular cash dividend has been paid in the last year.

How much of JAGX is sold short?

140.6K shares, 2.0% of float, as of Oct 15, 2026.

What sector is JAGX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · JAGXHealthcarePharmaceuticals

Jaguar Health, Inc. (JAGX)

$0.4988−10.53%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$0.50▼ 99.88% in range

Nov 4, 2025Low $0.50 · High $2067.19Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Jaguar Health closed at $0.50 on Nov 4, down 10.53%, within 0.0% of its 52-week closing low. Volume of 1.2M shares was 1.37× its 20-day average (above normal).

Split-adjusted performance: -82.2% over one month, -97.6% over six months, -99.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.23M, down 58.9% from a year earlier, with a net margin of -1036.8%.

Short interest was 140.6K shares at the Oct 15 settlement, up 67.0% from the prior report (2.0% of float, 1.0 days to cover).

Market cap$1.2M2.3M shares

Revenue · quarter$1.2M−58.9% YoY

Diluted EPS$-235.50—

P/E · TTM—P/S 0.0×

Net margin-1,036.8%Gross 15.8%

Dividend yieldNone

52-week range0.50 – 2067.19−100.0% from high

Volume1.2M1.37× 20-day avg

Volatility · 60d1,076.0%Annualised

Short % of float2.0%1.0 days to cover

Net cash-$11.8MCash $3.8M

Next earnings—Not scheduled

Split-adjusted performance

1W −76.2%1M −82.2%3M −92.9%6M −97.6%YTD −99.8%1Y −99.9%3Y −100.0%5Y −100.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum1

Revenue growth18

Net margin22

Value (low P/E)—

Size1

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short140.6K+67.0% vs prior

Days to cover1.0Settled Oct 15

% of float2.0%

Short vol. 10d43.8%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
JAGXJaguar Health	$0.4988	−10.53%	−97.6%	−58.9%	−1036.8%	—	$1.2M
MTNBMatinas BioPharma Holdings	$1.19	+4.39%	−88.3%	—	—	—	$1.2M	Compare
VBIOValion Bio	$0.5171	−2.60%	—	—	—	—	$1.1M	Compare
ARTLArtelo Biosciences	$2.27	−5.42%	−90.9%	—	—	—	$1.2M	Compare
GOVXGeoVax Labs, Inc. New	$0.1680	+2.38%	−89.8%	−100.0%	—	—	$1.5M	Compare
ELABPMGC Holdings	$1.92	−1.03%	−91.0%	—	−225.1%	—	$1.6M	Compare
KPTIKaryopharm Therapeutics	$0.0729	−17.44%	−99.2%	−11.9%	−200.5%	—	$1.7M	Compare
KAPAKairos Pharma	$0.4897	−3.03%	−87.4%	—	—	—	$1.7M	Compare
NXTSNexentis Technologies	$0.5550	−2.46%	—	—	—	—	$806.6K	Compare

News about Jaguar Health

All news →

No recent articles focused on Jaguar Health. 1 articles mention it in passing.

Quick answers

What does Jaguar Health do?: Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence.
What is JAGX's market cap?: $1.16M, based on the Nov 4 close of $0.50.
Does Jaguar Health pay a dividend?: No regular cash dividend has been paid in the last year.
How much of JAGX is sold short?: 140.6K shares, 2.0% of float, as of Oct 15, 2026.
What sector is JAGX in?: Healthcare, in the Pharmaceuticals industry.

About Jaguar Health

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

HQ: San Francisco, CA47 employeesListed May 13, 2015jaguar.health

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology